RxDoctor Payments Data

Durga Larkin, MD

Ophthalmology · South Kingstown, RINPI 1063466324

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,332 of the $3,863 with a category attached, or 60.4%. 14 manufacturers reported payments, led by Alcon at 34.3% of the total. Reporting peaked in 2024 at $1,580 and has fallen 58.5% since, to $657 in 2025.

$3,863in general payments, 2019–2025

Across 47 payments — averaging $82.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Johnson & Johnson Surgical Vision, Inc.$932
  • Glaukos Corporation$537
  • Alcon Research LLC$400
  • AbbVie$188
  • Aerie Pharmaceuticals, Inc.$123
  • plus $358 from 8 others

What the payments were for

  • Consulting fees$2,33260%
  • Food & beverage$1,53140%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,863 in reported general payments places this provider in the 80th percentile of 69 ophthalmology providers in Rhode Island.

See all ophthalmology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$317,746
Medicare patients
725
Services billed
2,748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium130$31,896
RestasisCyclosporine28$25,343
ProlensaBromfenac Sodium43$14,773
Prednisolone Acetate400$13,476
LumiganBimatoprost11$5,818
Travoprost39$5,448
Alphagan PBrimonidine Tartrate11$4,747
ErythromycinErythromycin Base391$4,453
Brinzolamide21$4,330
Ofloxacin217$3,796
SimbrinzaBrinzolamide/Brimonidine Tart11$3,727
Loteprednol Etabonate24$3,487
Latanoprost199$2,889
Timolol Maleate164$2,786
Doxycycline Monohydrate13$933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$188$35,90850 claims
AlconSimbrinza$1,325$3,72711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 ophthalmology providers in Rhode Island.

Other ophthalmology in South Kingstown

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →